Vaxcyte, Inc. 8-K

What Happened

• On May 6, 2026, Vaxcyte, Inc. announced its quarterly financial results for the quarter ended March 31, 2026 by issuing a press release. The press release is furnished as Exhibit 99.1 to the Form 8-K (Item 2.02) filed the same day.

Key Details

• Filing date: May 6, 2026 (Form 8-K, Item 2.02).
• Reporting period: Quarter ended March 31, 2026.
• Exhibit: Press release furnished as Exhibit 99.1 to the Form 8-K.
• Legal note: The information furnished (including Exhibit 99.1) is expressly noted as “furnished” — not “filed” — and therefore is not subject to Section 18 liability or automatically incorporated by reference into other registration statements (per Item 9.01 disclosure).

Why It Matters

• Quarterly earnings press releases provide the company’s updated results — such as revenue, net income/loss, cash position and any commentary on operations or guidance — and are material for assessing near-term performance. Because the detailed numbers and management commentary are contained in the press release (Exhibit 99.1), investors should review that exhibit and the company’s subsequent 10-Q for full financial statements and management discussion. Note that the exhibit is furnished, not filed, which affects its legal status under the securities laws.